BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced that Thomas E. Hughes, Ph.D., was elected to its Board of Directors on September 24, 2009. Dr. Hughes brings more than 20 years of drug discovery and development expertise to the company.
